California-based pharmacogenomics company Twist Bioscience has partnered with CeGaT, a provider of genetic diagnostics and next-generation sequencing (NGS) services, to launch the Twist Alliance CeGaT RNA Fusion Panel, a product designed to detect RNA fusions and perform transcript variant analysis for oncology research.

The Twist Alliance CeGaT RNA Fusion Panel combines Twist's RNA Library Prep and target enrichment capabilities with CeGaT's expertise in tumor diagnostics and panel design. The panel has over 150 fusion genes and detects RNA fusions, which are important biomarkers for studying cancer and can help identify molecular subtypes of cancers and monitor minimal residual disease.

Twist Biosciences is a synthetic biology and genomics company whose proprietary technology involves "writing" DNA on a silicon chip. This breakthrough method enables the rapid and cost-efficient production of high-quality synthetic DNA, which is a key driver in advancing drug discovery and development. The company’s product portfolio of synthetic DNA-based products, such as synthetic genes, NGS preparation tools, and antibody libraries, provides researchers with the necessary tools to investigate disease mechanisms, identify drug targets, and develop personalized therapies. Twist is also exploring long-term opportunities in digital data storage using DNA and biologics drug discovery.